Restriction endonucleases and T4 DNA ligase were purchased from New England Biolabs. iProof TM high-fidelity DNA polymerase were purchased from Bio-Rad Laboratories. All oligonucleotides were purchased from Integrated DNA Technologies. Media components for bacterial cultures were purchased from Difco laboratories. Chemicals were purchased from Sigma-Aldrich unless noted otherwise. Endoproteinase GluC (sequencing grade) was purchased from Roche Biosciences. Trypsin (modified, sequencing grade) was purchased from Worthington Biosciences.
reach a convergence with standard deviation of split frequencies < 0.01. Posterior probabilities were averaged over the final 75% of trees (25% burn in). The analysis utilized a mixed amino acid model with a proportion of sites designated invariant (+I), and rate variation among sites modeled after a gamma distribution (+G) divided into 8 categories, with all variable parameters estimated by the program based on random starting trees. Bayesian analyses were also performed for the separate alignments of the major subdivisions of each class of lanthipeptide synthetase, which normally show similar tree topologies and posterior probability supports. The figures of Bayesian phylograms were prepared by using TreeView (4) and MEGA4 (5) .
Maximum likelihood analyses were performed using the program PhyML (6) with the WAG+I+G+F (7) model, which was selected by using ProtTest (8) . Gamma distribution was divided into 8 categories and the tree topologies were estimated by SPR + NNI branch swapping, with 20 random starting trees. Branch support was determined by SH-like approximate likelihood-ratio test (aLRT) statistics (6, 9) .
Nucleotide base composition and codon usage analysis. GC 3s , the frequency of GC nucleotides present at the third position of synonymous codons, was analyzed for each lanthipeptide synthetase gene (Fig. S16A) . The effective number of codons (Nc) (10) used by lanthipeptide synthetase genes from firmicutes and actinobacteria was also analyzed and plotted against GC 3s (Nc-plot) (Fig. S16B ). GC content, GC 3s and Nc analysis were performed by using CodonW 1.4.2 (http://codonw.sourceforge.net/).
Cloning, production, and purification of modified NisA-ElxA. The fragment of the gene elxA encoding for the core peptide was amplified by PCR from Staphylococcus epidermidis 15X154 genomic DNA using primers NisA-ElxA-FP and NisA-ElxA-FP (for primer sequences, see Table  S6 ). A mutation that allows removal of the leader peptide with GluC was introduced in the primer. The PCR product contained annealing regions to the pRSF.His6-NisAB plasmid (11) , which encodes for hexahistidine tagged NisA and for untagged NisB, allowing replacement of the nisA core region for elxA by PCR amplification of the entire plasmid. After treatment with DpnI and transformation of E. coli DH5α cells, the plasmid pRSF.His6-NisAN-ElxAC.NisB was generated. This plasmid encodes for the hexahistidine tagged chimera NisA-ElxA and for NisB.
Electrocompetent E. coli BL21(DE3) cells were transformed with pRSF.His6-NisAN-ElxAC.NisB (negative control), or cotransformed with pRSF.His6-NisAN-ElxAC.NisB and pACYC.NisC (11) . Single colonies were inoculated in 5 mL of LB medium containing the appropriated antibiotics (50 μg/mL kanamycin and 12.5 μg/mL chloramphenicol) and grown for 12 h at 37 °C with shaking. Aliquots of 2.5 mL were used to inoculate 250 mL of LB medium containing the same antibiotics followed by incubation at 37 °C until OD 600 = 0.6. IPTG was added to a final concentration of 0.2 mM and the cultures were shaken for 20 h at 18 °C. The cells were harvested by centrifugation (6,500 × g for 20 min; Beckman JLA-10.500 rotor). The cell pellet was resuspended in 30 mL of denaturing buffer (6 M guanidine hydrochloride, 20 mM NaH 2 PO 4 , 500 mM NaCl, pH 7.5), and cell lysis was carried out using a MultiFlex C3 homogenizer (Avestin). The lysed cells were centrifuged at 23,700 × g for 60 min at 4 °C. The supernatant was loaded onto a HiTrap high-performance (HP) nickel affinity column (GE Healthcare) preequilibrated with start buffer (20 mM Tris, pH 8.0, 500 mM NaCl, 10% glycerol). The column was washed with wash buffer (start buffer containing 30 mM imidazole), and the peptide was eluted from the column with elution buffer (start buffer containing 500 mM imidazole).
The eluent was desalted using preparative scale RP-HPLC using a Waters Delta-pak C4 15 μm; 300 Å; 25 × 100 mm PrepPak Cartridge. A gradient of 2-100% of solvent B (0.086%TFA in 80% MeCN⁄20% water) was used (solvent A, 0.086% TFA in 2% MeCN⁄98% water). After lyophilization, the peptides were resuspended in buffer (50 mM HEPES, pH 7.5) and incubated with the endopeptidase GluC (2 ng/μL) at room temperature overnight to remove the leader peptide. Samples were analyzed directly by ESI-MS/MS, or were desalted by using ZipTipC18 before MALDI-MS analysis.
Construction of pET15b derivatives for expression of chimeric peptides containing the ProcA3.2 leader peptide. The genes for the chimeric peptide ProcA3.2-K-NisA and ProcA3.2-LctA were generated using nested PCR with previously reported expression plasmids as template. For ProcA-NisA, the DNA encoding the N-terminal region of the chimeric peptide (ProcA3.2 leader) was amplified using primers ProcA3.2 NdeI-FP and ProcA3.2Lea-LctAStr-Conn-RP (Table S6 ) with plasmid pET15b-ProcA3.2 (12) as template. The DNA encoding the C-terminal region of the chimeric peptide was amplified using primers ProcA3.2Lea-LctAStr-Conn-FP and LctA XhoI-RP with plasmid pET15b-LctA (13) as template. The primers ProcA3.2Lea-LctAStr-Conn-FP and ProcA3.2Lea-LctAStr-Conn-RP were designed to provide overlap of the two PCR products and the primers ProcA3.2 NdeI-FP and LctA XhoI-RP contained NdeI and XhoI restriction sites, respectively. The final insert was obtained by overlap extension PCR using the two products of the first two PCR reactions and subsequent amplification using the ProcA3.2 NdeI-FP and LctA XhoI-RP primers. The chimeric peptide gene was then cloned into a pET15b vector between the NdeI and XhoI restriction sites. The sequences of the resulting plasmid (pET15b-ProcA 3.2Lea-LctAStr) was confirmed by DNA sequencing.
For constructing the gene encoding ProcA3.2-K-NisA, the DNA encoding the N-terminal region of the chimeric peptide was again amplified using primers ProcA3.2 NdeI-FP and ProcA3.2Lea-K-NisAStr-Conn-RP with plasmid pET15b-ProcA3.2 as template. The DNA encoding the C-terminal region of the chimeric peptide was amplified using primers ProcA3.2Lea-K-NisAStr-Conn-FP and NisA XhoI-RP with plasmid pET15b-NisA (14) as template. The primers ProcA3.2Lea-K-NisAStr-Conn-FP and ProcA3.2Lea-K-NisAStr-Conn-RP were designed to provide overlap of the two PCR products and to introduce a Lys at the junction of the leader and core peptide for cleavage with trypsin, and the primers ProcA3.2 NdeI-FP and NisA XhoI-RP contained NdeI and XhoI restriction sites, respectively. The final insert was obtained by overlap extension PCR using the two products of the first two PCR reactions, and subsequent amplification using the ProcA3.2 NdeI-FP and NisA XhoI-RP. The chimeric peptide gene was then cloned into a pET15b vector between the NdeI and XhoI restriction sites. The sequences of the resulting plasmid (pET15b-ProcA 3.2Lea-K-NisAStr) was confirmed by DNA sequencing.
Construction of pRSFDuet-1 derivatives for co-expression of ProcM and chimeric peptides containing the ProcA3.2 leader peptide. The procM gene was inserted into multiple cloning site-2 of the pRSFDuet-1 vector between the NdeI and KpnI restriction sites (11) . The chimeric peptide genes were amplified using their pET15b constructs (see above) as templates and the primer pairs ProcA3.2 EcoRI-FP and LctA NotI-RP, ProcA3.2 EcoRI-FP and NisA NotI-RP, respectively. The PCR fragments were then individually cloned between the EcoRI and NotI restriction sites of multiple cloning site-1 of the pRSFDuet-1 vector with the procM gene already inserted in the multiple cloning site-2. The sequences of the resulting plasmids (pRSF-Duet1-ProcA3.2Lea-LctAStr/ProcM, and pRSF-Duet1-ProcA3.2Lea-K-NisAStr/ProcM) were confirmed by DNA sequencing.
Overexpression and purification of ProcM-modified chimeric peptides. Electrocompetent E. coli BL21 (DE3) cells were transformed with the pET15b constructs containing the N-terminal hexa-histidine chimeric peptide fusion gene or the pRSF-Duet1 constructs containing both the N-terminal hexa-histidine chimeric peptide fusion gene and procM. Overexpression and purification of chimeric peptide were performed as described for NisA-ElxA.
Iodoacetamide assays for detection of free cysteines. A peptide sample (~ 50 M) was incubated in 250 mM Tris (pH = 9), 25 mM iodoacetamide, and 1 mM TCEP in the dark at 25 o C for 3 h. Samples were desalted using Zip-TipC18 and subjected to MALDI-TOF MS analysis. ) of the indicator strain. After agar solidification in a Petri dish, samples were applied to a small well created in the medium, and the plates were incubated at 30 o C for 15-20 h. A similar procedure was used for bioactivity assays with ProcA3.2-LctA and ProcA3.2-K-NisA against Lactococcus lactis HP grown on GM17 agar (4% M17, 0.5% glucose, 1.5% agar).
Tandem mass spectrometry analysis. The peptides of interest were separated from leader peptide-derived peptides by UPLC using a gradient of 3% mobile phase A (0.1% formic acid in water) to 97 % mobile phase B (0.1% formic acid in methanol) over 12 min. The instrument settings used included capillary voltage and cane voltage of 3500 V and 40 V respectively, 120 °C as source temperature; 300 °C as desolvation temperature, cone gas flow of 150 L/h, and desolvation gas flow of 600 L/h. A transfer collision energy of 4 V was used, while the trap collision energy was set to 20 to 30 V for MSMS. Fig. 2A and 2B in the main text. The Bayesian posterior probability (bPP) and the maximum likelihood nonparametric aLRT statistics are shown as bPP/aLRT, or if space did not allow, they are shown above and below the lines, respectively. If the branch is not present in the maximum likelihood tree, support is indicated as a "-"; if the branch was present but with low statistic support (aLRT < 50), it is indicated as a "C". (15) and thiopeptide (16) biosynthesis were not suitable for using as the outgroup because of their low sequence similarities with LanB enzymes (e.g. the global sequence identities of GodF for goadsporin biosynthesis and TsrC/TsrJ for thiostrepton biosynthesis with NisB calculated by the Needleman-Wunsch algorithm (2) are 2.0% and 0.2%, respectively; the same calculation for any two LanBs are normally >20%). Therefore, the LanB trees were rooted by using all members of a sister clade of enzymes as the outgroup (17) . Bayesian inferences of posterior probabilities are indicated by line width. Lanthipeptides in each tree are shown by differently colored boxes according to their structural types. Lanthipeptides proposed in this study are shown in yellow font.
Fig. S5.
Statistical support for the LanB phylogeny. The Bayesian posterior probability (bPP) and the maximum likelihood nonparametric aLRT statistics are shown as bPP/aLRT, or if space did not allow, they are shown above and below the lines, respectively. If the branch is not present in the maximum likelihood tree, support is indicated as a "-"; if the branch was present but with low statistic support (aLRT < 50), it is indicated as a "C".
Fig. S6.
Structures of streptin and the proposed analog streptin B.
Fig. S7.
Statistical support for the LanM phylogeny. The Bayesian posterior probability (bPP) and the maximum likelihood nonparametric aLRT statistics are shown as bPP/aLRT, or if space did not allow, they are shown above and below the lines, respectively. If the branch is not present in the maximum likelihood tree, support is indicated as a "-"; if the branch was present but with low statistic support (aLRT < 50), it is indicated as a "C". Comparing with the GC contents the GC 3s values are much lower for genes with GC contents < 0.5 and much higher for genes with GC contents > 0.5, possibly owing to the nucleotide compositional constraints. Mostly, the GC 3s index shares the same trends as that of GC content, suggesting that the analysis is not biased by the codon preference of different organisms. (B) Nc-plot of lanthipeptide synthetase genes from firmicutes and actinobacteria. Nc values represent the bias away from equal usage of codons within synonymous groups (10) . A value of 61 means that all codons are used equally for all amino acids; a value of 20 is found when only one codon is used for each amino acid. Both Nc and GC 3s are not sensitive to gene length and are independent of associated genome background (10), allowing for a comparative analysis of the patterns of synonymous codon usage bias of lanthipeptide synthetase genes from different organisms. The red line shows the theoretically expected correlation of GC 3s and Nc under the assumption of only mutational bias with no natural selection for the genes, which can be described as Nc = 2 + GC 3s + 29/[(CG 3s ) 2 + (1 -GC 3s ) 2 ] (10). "B" in the Nc-plot denotes the bifidobacterial genes. Most of the firmicutes genes have Nc values close to the red line, indicating that most of the firmicutes genes have not been subjected to selections such as selection for transcriptional and translational efficiency. Alternatively, it could represent rapid evolution of the firmicute genes. On the contrary, most of the actinobacterial genes show some deviations from the red line, suggesting the codons of these genes have been optimized to some extent. These results reflect the dynamic evolutionary process of lanthipeptide synthetases, particularly in firmicutes strains. Table S1 . Statistic analysis of the GC content deviation for the selected 25 core genes in Streptococcus strains. These 25 genes include adenine phosphoribosyltransferase (Apt), Elongation factor Ts (EF-Ts), holliday junction DNA helicase protein RuvB, DNA repair protein RecN, DNA repair protein RadA, ATP-dependent DNA helicase RecG, A/G-specific adenine glycosylase, 50S ribosomal protein L11 methyltransferase (PrmA), leucyl-tRNA synthetase, glutamyl-tRNA synthetase, threonyl-tRNA synthetase, asparaginyl-tRNA synthetase, tryptophanyl-tRNA synthetase, tyrosyl-tRNA synthetase, histidyl-tRNA synthetase, lysyl-tRNA synthetase, phenylalanyl-tRNA synthetase alpha subunit, phenylalanyl-tRNA synthetase beta subunit, alanyl-tRNA synthetase, isoleucyl-tRNA synthetase, valyl-tRNA synthetase, glycyl-tRNA synthetase alpha subunit, arginyl-tRNA synthetase, prolyl-tRNA synthetase, seryl-tRNA synthetase.
Strain
Accession number Genome GC (%) Mean GC (%) Standard deviation (σ) (%) Table S6 . Primer sequences (5' to 3').
NisA-ElxA-FP GAAAGATTCAGGTGCATCACCAGAGTCAGCTAGTATTG 
